Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll, +53

The Lancet

OncologyClinical TranslationOriginator InfliximabClinical TrialsClinical Evidence +8

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, +30

JAMA

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, +30

JAMA

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton, +45

Journal of Internal Medicine

Human epididymis protein 4 reference limits and natural variation in a Nordic reference population

Nils Bolstad, Miriam Øijordsbakken, Kjell Nustad, +1

Tumor Biology

Healthy SubjectsNatural VariationGeneticsGenetic EpidemiologyEpidemiologic Research +16

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer

Ann Rita Halvorsen, Maria Moksnes Bjaanæs, Marissa LeBlanc, +9

Oncotarget

Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial

Kristin Ranheim Randel, Anna Lisa Schult, Edoardo Botteri, +17

Gastroenterology

Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA

Ingvild Paur, Wolfgang Lilleby, Siv Kjølsrud Bøhn, +16

Clinical Nutrition

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome

Maria Thomsen, Eva Skovlund, Halfdan Sørbye, +9

British Journal of Cancer

Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population

Marte Lie Høivik, L. Buer, Milada Cvancarova, +4

Scandinavian Journal of Gastroenterology